SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Evercore ISI Maintains NovoCure Outperform, Cuts Price Target to $20

Evercore ISI maintained its Outperform rating on NovoCure and lowered its price target to $20 from $23.

NVCR

Related stories